Home Endocrinology & Hormones Glucocorticoid Receptor agonist Deflazacort

research use only

Deflazacort Glucocorticoid Receptor agonist

Deflazacort (MDL 458) is a glucocorticoid used as an anti-inflammatory and immunosuppressant.

Deflazacort Glucocorticoid Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 441.52

Purity & Quality Control

Batch: S188801 DMSO]88 mg/mL]false]Ethanol]12 mg/mL]false]Water]Insoluble]false Purity: 99.91%
99.91

Related Products

Mechanism of Action

Targets
Glucocorticoid receptor [1]

In Vivo
In vivo Deflazacort results in a significant and equal decrease of thymus weight, indicating a marked reduction in total immunogenic tissue in rats. [1] This compound reduces thymus weight and Daily weight gain in rats. It lowers liver IFG-I and GHR mRNA in rats. [2] This chemical is a heterocyclic glucocorticoid with anti-inflammatory activity but with decreased side effects. It and [3H]dexamethasone (DEX) similarly induce in vivo ornithine decarboxylase activity in hippocampus and liver, although body weight loss after chronic treatment is significantly less for DFC. [3] This compound induces dose-dependent decreases in osteocalcin (OC) plasma production rate (PPR). It and prednisolone increase both postabsorptive plasma glucose and plasma calcium levels in sheep, but there are no significant differences between their effects. [4] This compound, especially combined with L-arginine, spares quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise. It alone prevents the typical progressive loss of function (measured as voluntary distance run over 24 hours) that is observed 3 months later in placebo-treated mice. [5] It causes a less significant alteration in the pattern of GH secretion and does not negatively affect the overall amount of GH secreted. [6]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04791345 Unknown status
Healthy Volunteers
Parc de Salut Mar
 February 26 2021 Phase 1
NCT03783923 Terminated
Limb-Girdle Muscular Dystrophy
PTC Therapeutics
 October 31 2019 Phase 3
NCT03642145 Withdrawn
Duchenne Muscular Dystrophy
PTC Therapeutics
 October 31 2018 Phase 3
NCT02251600 Completed
Duchenne Muscular Dystrophy
PTC Therapeutics
 December 2014 Phase 1
NCT02286622 Completed
Renal Impairment
PTC Therapeutics
 December 2014 Phase 1

References
  • https://pubmed.ncbi.nlm.nih.gov/22192593/
  • https://pubmed.ncbi.nlm.nih.gov/7804450/
  • https://pubmed.ncbi.nlm.nih.gov/8003438/
  • https://pubmed.ncbi.nlm.nih.gov/8402319/
  • https://pubmed.ncbi.nlm.nih.gov/16464957/
  • https://pubmed.ncbi.nlm.nih.gov/10229911/

Chemical Information

Molecular Weight 441.52 Formula

C25H31NO6
CAS No. 14484-47-0 SDF Download SDF
Synonyms MDL 458
Smiles CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C

Storage and Stability

Storage (From the date of receipt)

In vitro
Batch:

DMSO : 88 mg/mL ( (199.31 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 12 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.